M&A: Omada-Physera. Optum-AbleTo. Elekta-Kaiku.

Issue 053.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about a Senate bill that seeks reimbursement for prescription digital therapeutics. Next week I'm hoping to get wonky about how a piece of software gets coded like a drug. Here's what's happening this week:

Unusual way to kick off Year Two of E&O: After I suggested that Omada should (and probably would) acquire digital MSK provider Physera last weekend in a rare open-access post on E&O, a few days later Omada did just that. So... welcome to all the new readers, and please ratchet your expectations way, way down.
Big Health wrote a white paper on the cost-effectiveness of its Sleepio product earlier this month:

"The study assessed baseline healthcare costs for 1,102 employees (551 Sleepio users and 551 controls) during an initial 12-month timeframe, before Sleepio was

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

M&A: Omada-Physera. Optum-AbleTo. Elekta-Kaiku.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.